Ifosfamide is a cytotoxic drug for the treatment of malignant disease. As a single agent it has successfully produced objective remissions in a wide range of malignant conditions. Ifosfamide is also frequently used in combination with other cytotoxic drugs, radiotherapy and surgery.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
5 - 12 g per m² of body surface area (BSA)
From 5 To 12 g per m² of body surface area (BSA) once every day
A guide to the dosage regimens used for most indications is given below:
The frequency of dosage is determined by the degree of myelosuppression and the time taken to recover adequate bone marrow function. The usual number of courses given is 4, but up to 7 (6 by 24 hour infusion) courses have been given. Re-treatment has been given following relapse.
During or immediately after administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urothelial toxicity.
For prophylaxis of haemorrhagic cystitis, ifosfamide should be used in combination with mesna.